Mipharm S.p.A. was born in January 1998 following the merger of Sandoz and Ciba Geigy, from which resulted the new company Novartis. Mipharm was founded by a group of ex managers coming from Novartis by mean of a spin-off of the manufacturing site located in Milan, Via Quaranta, previously owned by Sandoz.  
In December 2016, Mandarin Capital Partners II acquired the majority stake in Mipharm share capital.
Today, Mipharm is one of the most valuable third party manufacturing and new product development sites in Italy and it claims to have four FDA approvals (Nasal Spray Solution, Oral Potent Drug, Sachet, Packaging). 
Mipharm has been investing significant resources to continuously improve manufacturing site qualitative standard and currently it is able to produce and to pack a huge range of products and pharmaceutical forms.

Pharmaceutical

MIPHARM SPA

MIPHARM SPA's headquarters in Milan, Italy

This department oversees the overall strategic direction and operational management of the organization.

Executive Management

This department ensures that products meet quality standards through rigorous testing and analysis.

Quality Assurance

This department is responsible for ensuring the quality and safety of products through chemical and microbiological analysis.

Quality Control

This department oversees quality assurance and control processes to ensure product standards and compliance.

Quality Management

This department is responsible for testing and ensuring the quality of products through laboratory analysis.

Quality Control Laboratory

This department manages employee relations, recruitment, and organizational development.

People (2)

Jobs (0)

Other teams

Quality Assurance

Quality Control

Quality Management

Quality Control Laboratory

Human Resources